FDA delays approval of Bristol-Myers' belatacept

05/2/2010 | Reuters

Bristol-Myers Squibb has received a complete-response letter from the FDA for its kidney-transplant drug belatacept. The agency asked for additional data on the long-term effects of the treatment as well as the company's risk evaluation and mitigation plan for the product.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA